REGENXBIO (RGNX) Stock Forecast, Price Target & Predictions
RGNX Stock Forecast
REGENXBIO stock forecast is as follows: an average price target of $38.00 (represents a 193.44% upside from RGNX’s last price of $12.95) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RGNX Price Target
The average price target for REGENXBIO (RGNX) is $38.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $35.00. This represents a potential 193.44% upside from RGNX's last price of $12.95.
RGNX Analyst Ratings
According to 5 Wall Street analysts, REGENXBIO's rating consensus is 'Buy'. The analyst rating breakdown for RGNX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
REGENXBIO Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Yi Chen | H.C. Wainwright | $39.00 | $11.38 | 242.86% | 201.16% |
| Jun 24, 2024 | Annabel Samimy | Stifel Nicolaus | $40.00 | $12.79 | 212.74% | 208.88% |
| Jun 07, 2024 | Paul Choi | Goldman Sachs | $38.00 | $13.76 | 176.16% | 193.44% |
| May 15, 2024 | Yi Chen | H.C. Wainwright | $38.00 | $15.80 | 140.51% | 193.44% |
| Mar 11, 2024 | Yi Chen | H.C. Wainwright | $36.00 | $22.85 | 57.55% | 177.99% |
| Mar 08, 2024 | Luca Issi | RBC Capital | $35.00 | $22.75 | 53.85% | 170.27% |
The latest REGENXBIO stock forecast, released on Sep 05, 2024 by Yi Chen from H.C. Wainwright, set a price target of $39.00, which represents a 242.86% increase from the stock price at the time of the forecast ($11.38), and a 201.16% increase from RGNX last price ($12.95).
REGENXBIO Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 6 |
| Avg Price Target | $39.00 | $39.50 | $37.67 |
| Last Closing Price | $12.95 | $12.95 | $12.95 |
| Upside/Downside | 201.16% | 205.02% | 190.89% |
In the current month, the average price target of REGENXBIO stock is $39.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 201.16% increase as opposed to REGENXBIO's last price of $12.95. This month's average price target is down -1.27% compared to last quarter, and up 3.53% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 05, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Aug 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 07, 2024 | Goldman Sachs | - | Buy | Initialise |
| May 15, 2024 | Wedbush | Buy | Buy | Hold |
| May 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 12, 2024 | Wedbush | Buy | Buy | Hold |
| Mar 08, 2024 | RBC Capital | - | Outperform | Upgrade |
REGENXBIO's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave RGNX a "Buy" rating, the same as its previous rate.
REGENXBIO Financial Forecast
REGENXBIO Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $22.21M | $28.91M | $19.98M | $19.14M | $31.34M | $26.51M | - | $22.22M | - | $30.77M | $22.04M | $18.88M | $21.45M | $98.91M | $16.57M | $17.64M | $11.77M | $14.70M | $7.88M | $884.00K | $40.78M | $5.31M |
| Avg Forecast | $71.03M | $28.23M | $144.32M | $20.95M | $24.10M | $23.47M | $22.97M | $23.52M | $34.01M | $26.14M | $34.50M | $31.22M | $37.45M | $30.81M | $28.31M | $27.22M | $427.83M | $33.17M | $21.17M | $18.59M | $26.31M | $21.45M | $20.46M | $19.62M | $39.67M | $7.46M | $22.61M | $854.20K | $126.04M | $4.17M |
| High Forecast | $100.09M | $39.78M | $203.36M | $29.52M | $33.96M | $26.98M | $32.37M | $33.15M | $50.11M | $36.83M | $48.62M | $43.98M | $52.77M | $43.42M | $28.31M | $38.12M | $599.27M | $46.46M | $29.66M | $26.03M | $36.85M | $30.04M | $28.66M | $27.49M | $55.57M | $10.44M | $31.68M | $1.03M | $151.25M | $5.00M |
| Low Forecast | $45.50M | $18.08M | $92.44M | $13.42M | $15.44M | $17.37M | $14.71M | $15.07M | $24.82M | $16.74M | $22.10M | $19.99M | $23.99M | $19.74M | $28.31M | $20.76M | $326.34M | $25.30M | $16.15M | $14.18M | $20.06M | $16.36M | $15.61M | $14.97M | $30.26M | $5.69M | $17.25M | $683.36K | $100.83M | $3.34M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 10 | 10 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | 0.65% | 1.11% | 0.58% | 0.61% | 0.84% | 0.86% | - | 0.82% | - | 0.93% | 1.04% | 1.02% | 0.82% | 4.61% | 0.81% | 0.90% | 0.30% | 1.97% | 0.35% | 1.03% | 0.32% | 1.27% |
REGENXBIO's average Quarter revenue forecast for Mar 24 based on 3 analysts is $23.52M, with a low forecast of $15.07M, and a high forecast of $33.15M. RGNX's average Quarter revenue forecast represents a 5.91% increase compared to the company's last Quarter revenue of $22.21M (Dec 23).
REGENXBIO EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 10 | 10 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $-63.90M | $-64.90M | $-73.11M | $-66.09M | $-57.69M | $-67.48M | - | $-68.84M | $313.60M | $-48.87M | $-49.07M | $-41.50M | $-37.62M | $10.96M | $-32.13M | $-38.04M | $-26.93M | $-32.88M | $163.00K | $-30.68M | $7.24M | $-19.55M |
| Avg Forecast | $-48.33M | $-19.21M | $-98.20M | $-14.25M | $-16.40M | $-15.97M | $-15.63M | $-38.30M | $-23.14M | $-17.79M | $-23.48M | $-40.97M | $-25.48M | $-25.15M | $-19.27M | $-43.82M | $-291.11M | $-22.86M | $-36.35M | $-44.10M | $-17.90M | $-14.59M | $-31.41M | $-28.86M | $-10.77M | $-22.23M | $283.78K | $-29.61M | $15.14M | $-14.22M |
| High Forecast | $-30.96M | $-12.30M | $-62.90M | $-9.13M | $-10.50M | $-11.82M | $-10.01M | $-30.64M | $-16.89M | $-11.39M | $-15.04M | $-32.77M | $-16.32M | $-20.12M | $-19.27M | $-35.05M | $-222.05M | $-18.29M | $-29.08M | $-35.28M | $-13.65M | $-11.13M | $-25.13M | $-23.09M | $-8.62M | $-17.78M | $340.54K | $-23.69M | $18.16M | $-11.38M |
| Low Forecast | $-68.10M | $-27.07M | $-138.37M | $-20.09M | $-23.11M | $-18.36M | $-22.03M | $-45.97M | $-34.09M | $-25.06M | $-33.08M | $-49.16M | $-35.91M | $-30.18M | $-19.27M | $-52.58M | $-407.75M | $-27.43M | $-43.62M | $-52.92M | $-25.07M | $-20.44M | $-37.69M | $-34.63M | $-12.93M | $-26.68M | $227.02K | $-35.54M | $12.11M | $-17.06M |
| Surprise % | - | - | - | - | - | - | - | - | 2.76% | 3.65% | 3.11% | 1.61% | 2.26% | 2.68% | - | 1.57% | -1.08% | 2.14% | 1.35% | 0.94% | 2.10% | -0.75% | 1.02% | 1.32% | 2.50% | 1.48% | 0.57% | 1.04% | 0.48% | 1.38% |
2 analysts predict RGNX's average Quarter EBITDA for Mar 22 to be $-43.82M, with a high of $-35.05M and a low of $-52.58M. This is -113.97% lower than REGENXBIO's previous annual EBITDA (Dec 21) of $313.60M.
REGENXBIO Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 10 | 10 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $-62.89M | $-61.87M | $-72.06M | $-69.95M | $-59.94M | $-79.92M | - | $-76.72M | $307.02M | $-58.41M | $-57.64M | $-50.14M | $-46.24M | $8.79M | $-33.76M | $-40.04M | $-26.46M | $-34.58M | $-1.46M | $-32.23M | $4.31M | $-19.20M |
| Avg Forecast | $-22.10M | $-55.32M | $45.03M | $-59.84M | $-51.25M | $-56.68M | $-65.35M | $-43.19M | $-64.28M | $-73.71M | $-60.04M | $-46.19M | $-64.90M | $-30.06M | $-64.25M | $-49.40M | $338.48M | $-27.32M | $-42.70M | $-53.27M | $-48.88M | $17.63M | $-33.00M | $-30.37M | $-10.59M | $-23.38M | $-2.54M | $-31.10M | $9.00M | $-13.97M |
| High Forecast | $-11.77M | $-29.47M | $68.98M | $-31.87M | $-27.30M | $-53.26M | $-34.81M | $-34.55M | $-59.22M | $-39.26M | $-31.98M | $-36.95M | $-34.57M | $-24.04M | $-64.25M | $-39.52M | $514.79M | $-21.86M | $-34.16M | $-42.62M | $-33.81M | $21.15M | $-26.40M | $-24.30M | $-8.47M | $-18.70M | $-2.03M | $-24.88M | $10.81M | $-11.17M |
| Low Forecast | $-33.85M | $-84.74M | $23.99M | $-91.65M | $-78.51M | $-62.54M | $-100.10M | $-51.83M | $-69.85M | $-112.90M | $-91.97M | $-55.43M | $-99.41M | $-36.07M | $-64.25M | $-59.29M | $234.10M | $-32.79M | $-51.23M | $-63.93M | $-74.35M | $14.10M | $-39.60M | $-36.45M | $-12.70M | $-28.06M | $-3.04M | $-37.32M | $7.20M | $-16.76M |
| Surprise % | - | - | - | - | - | - | - | - | 0.98% | 0.84% | 1.20% | 1.51% | 0.92% | 2.66% | - | 1.55% | 0.91% | 2.14% | 1.35% | 0.94% | 0.95% | 0.50% | 1.02% | 1.32% | 2.50% | 1.48% | 0.57% | 1.04% | 0.48% | 1.38% |
REGENXBIO's average Quarter net income forecast for Mar 22 is $-49.40M, with a range of $-59.29M to $-39.52M. RGNX's average Quarter net income forecast represents a -116.09% decrease compared to the company's last Quarter net income of $307.02M (Dec 21).
REGENXBIO SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 10 | 10 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $19.08M | $23.08M | $23.70M | $22.63M | $21.21M | $20.92M | - | $22.32M | $22.04M | $21.03M | $18.43M | $17.84M | $17.57M | $15.86M | $15.55M | $14.90M | $14.49M | $12.41M | $13.34M | $11.56M | $11.15M | $9.01M |
| Avg Forecast | $53.83M | $21.40M | $109.38M | $15.88M | $18.27M | $17.79M | $17.41M | $12.56M | $25.78M | $19.81M | $26.15M | $13.44M | $28.38M | $10.82M | $21.46M | $14.37M | $324.24M | $9.84M | $13.65M | $14.09M | $19.94M | $16.25M | $15.20M | $11.30M | $5.80M | $5.65M | $17.14M | $647.38K | $23.33M | $3.16M |
| High Forecast | $75.86M | $30.15M | $154.12M | $22.37M | $25.74M | $20.45M | $24.53M | $15.08M | $37.97M | $27.91M | $36.85M | $16.12M | $39.99M | $12.99M | $21.46M | $17.25M | $454.17M | $11.81M | $16.38M | $19.73M | $27.92M | $22.77M | $18.25M | $13.56M | $6.96M | $7.91M | $24.01M | $776.85K | $27.99M | $3.79M |
| Low Forecast | $34.48M | $13.70M | $70.05M | $10.17M | $11.70M | $13.16M | $11.15M | $10.05M | $18.81M | $12.69M | $16.75M | $10.75M | $18.18M | $8.66M | $21.46M | $11.50M | $247.33M | $7.87M | $10.92M | $10.74M | $15.21M | $12.40M | $12.16M | $9.04M | $4.64M | $4.31M | $13.07M | $517.90K | $18.66M | $2.53M |
| Surprise % | - | - | - | - | - | - | - | - | 0.74% | 1.17% | 0.91% | 1.68% | 0.75% | 1.93% | - | 1.55% | 0.07% | 2.14% | 1.35% | 1.27% | 0.88% | 0.98% | 1.02% | 1.32% | 2.50% | 2.20% | 0.78% | 17.85% | 0.48% | 2.85% |
REGENXBIO's average Quarter SG&A projection for Mar 24 is $12.56M, based on 3 Wall Street analysts, with a range of $10.05M to $15.08M. The forecast indicates a -34.15% fall compared to RGNX last annual SG&A of $19.08M (Dec 23).
REGENXBIO EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 10 | 10 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-1.43 | $-1.41 | $-1.66 | $-1.61 | $-1.38 | $-1.85 | - | $-1.79 | $7.18 | $-1.37 | $-1.36 | $-1.20 | $-1.24 | $0.24 | $-0.91 | $-1.08 | $-0.72 | $-0.94 | $-0.04 | $-0.89 | $0.12 | $-0.56 |
| Avg Forecast | $-0.44 | $-1.09 | $0.89 | $-1.18 | $-1.01 | $-1.12 | $-1.29 | $-1.26 | $-1.27 | $-1.46 | $-1.19 | $-1.42 | $-1.28 | $-1.47 | $-1.40 | $-1.54 | $7.69 | $-1.03 | $-1.12 | $-1.28 | $-1.11 | $-1.00 | $-0.89 | $-0.84 | $-0.67 | $-0.71 | $-0.58 | $-0.86 | $-0.71 | $-0.32 |
| High Forecast | $-0.23 | $-0.58 | $1.36 | $-0.63 | $-0.54 | $-1.05 | $-0.69 | $-0.67 | $-1.17 | $-0.78 | $-0.63 | $-0.76 | $-0.68 | $-0.78 | $-1.40 | $-1.06 | $11.70 | $-0.71 | $-0.77 | $-0.89 | $-0.77 | $-0.69 | $-0.61 | $-0.58 | $-0.46 | $-0.49 | $-0.40 | $-0.60 | $-0.57 | $-0.26 |
| Low Forecast | $-0.67 | $-1.67 | $0.47 | $-1.81 | $-1.55 | $-1.24 | $-1.98 | $-1.93 | $-1.38 | $-2.23 | $-1.82 | $-2.18 | $-1.96 | $-2.25 | $-1.40 | $-2.34 | $5.32 | $-1.57 | $-1.70 | $-1.95 | $-1.69 | $-1.52 | $-1.35 | $-1.27 | $-1.01 | $-1.09 | $-0.88 | $-1.31 | $-0.85 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | 1.13% | 0.97% | 1.40% | 1.13% | 1.08% | 1.26% | - | 1.16% | 0.93% | 1.33% | 1.22% | 0.94% | 1.12% | -0.24% | 1.02% | 1.29% | 1.08% | 1.32% | 0.07% | 1.03% | -0.17% | 1.75% |
According to 2 Wall Street analysts, REGENXBIO's projected average Quarter EPS for Mar 22 is $-1.54, with a low estimate of $-2.34 and a high estimate of $-1.06. This represents a -121.44% decrease compared to RGNX previous annual EPS of $7.18 (Dec 21).
REGENXBIO Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| QURE | uniQure | $5.62 | $53.67 | 854.98% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| PASG | Passage Bio | $0.73 | $6.00 | 721.92% | Buy |
| PLRX | Pliant Therapeutics | $12.60 | $39.71 | 215.16% | Buy |
| RGNX | REGENXBIO | $12.95 | $38.00 | 193.44% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.76 | $38.80 | 181.98% | Buy |
| FDMT | 4D Molecular Therapeutics | $16.16 | $44.57 | 175.80% | Buy |
| IMCR | Immunocore | $33.90 | $77.43 | 128.41% | Buy |
| STOK | Stoke Therapeutics | $15.12 | $33.75 | 123.21% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| RCKT | Rocket Pharmaceuticals | $21.80 | $46.75 | 114.45% | Buy |
| MIRM | Mirum Pharmaceuticals | $40.29 | $54.50 | 35.27% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.77 | $52.17 | 19.19% | Buy |
| RNA | Avidity Biosciences | $42.19 | $50.00 | 18.51% | Buy |
| PTGX | Protagonist Therapeutics | $44.91 | $50.00 | 11.33% | Buy |
RGNX Forecast FAQ
Is REGENXBIO a good buy?
Yes, according to 5 Wall Street analysts, REGENXBIO (RGNX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of RGNX's total ratings.
What is RGNX's price target?
REGENXBIO (RGNX) average price target is $38 with a range of $35 to $40, implying a 193.44% from its last price of $12.95. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will REGENXBIO stock go up soon?
According to Wall Street analysts' prediction for RGNX stock, the company can go up by 193.44% (from the last price of $12.95 to the average price target of $38), up by 208.88% based on the highest stock price target, and up by 170.27% based on the lowest stock price target.
Can REGENXBIO stock reach $20?
RGNX's average twelve months analyst stock price target of $38 supports the claim that REGENXBIO can reach $20 in the near future.
What is REGENXBIO's current price target trend?
1 Wall Street analyst forecast a $39 price target for REGENXBIO (RGNX) this month, up 201.16% from its last price of $12.95. Compared to the last 3 and 12 months, the average price target increased by 205.02% and increased by 190.89%, respectively.
What are REGENXBIO's analysts' financial forecasts?
REGENXBIO's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $94.07M (high $126.46M, low $62.59M), average EBITDA is $-86.306M (high $-62.977M, low $-109M), average net income is $-216M (high $-150M, low $-293M), average SG&A $66.03M (high $85.8M, low $46.06M), and average EPS is $-4.684 (high $-2.951, low $-6.694). RGNX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $264.54M (high $372.75M, low $169.43M), average EBITDA is $-180M (high $-115M, low $-254M), average net income is $-92.22M (high $-4.122M, low $-186M), average SG&A $200.49M (high $282.5M, low $128.41M), and average EPS is $-1.822 (high $-0.0815, low $-3.681).
Did the RGNX's actual financial results beat the analysts' financial forecasts?
Based on REGENXBIO's last annual report (Dec 2023), the company's revenue was $90.24M, which missed the average analysts forecast of $125.87M by -28.31%. Apple's EBITDA was $-268M, beating the average prediction of $-105M by 154.46%. The company's net income was $-263M, beating the average estimation of $-244M by 7.89%. Apple's SG&A was $88.49M, beating the average forecast of $85.17M by 3.90%. Lastly, the company's EPS was $-6.02, beating the average prediction of $-5.334 by 12.85%. In terms of the last quarterly report (Dec 2023), REGENXBIO's revenue was $22.21M, missing the average analysts' forecast of $34.01M by -34.69%. The company's EBITDA was $-63.903M, beating the average prediction of $-23.142M by 176.14%. REGENXBIO's net income was $-62.889M, missing the average estimation of $-64.281M by -2.17%. The company's SG&A was $19.08M, missing the average forecast of $25.78M by -25.98%. Lastly, the company's EPS was $-1.43, beating the average prediction of $-1.27 by 12.57%